

**Codex Alimentarius Commission**

**40<sup>th</sup> Session**

**Geneva, 17 – 22 July 2017**

**European Union comments on the  
Proposed draft MRLs for lasalocid sodium, ivermectin and teflubenzuron  
at step 5/8  
(CL 2016/38-RVDF)**

*European Union Competence*

*European Union Vote*

 **Lasalocid sodium**

The European Union (EU) would like to reiterate its reservation to the adoption of the proposed draft MRLs for lasalocid sodium at step 5/8.

The EU considers that a risk to consumers cannot be ruled out, as in the absence of a methodology for derivation of a microbiological acute reference dose, there is no health-based guidance value with which to satisfactorily compare the acute exposure.

 **Ivermectin**

**1. Proposed Draft MRL for ivermectin for muscle**

The EU can support the proposed draft MRL.

**2. Proposed draft MRLs for ivermectin for fat, kidneys and liver**

The EU does not object to the proposed draft MRLs for ivermectin in fat, kidneys and liver.

 **Teflubenzuron**

The EU does not object to the proposed draft MRLs for teflubenzuron.